Search details
1.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38621400
2.
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
BMC Med
; 20(1): 112, 2022 03 25.
Article
in English
| MEDLINE | ID: mdl-35331214
3.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34028967
4.
Dose considerations for anti-cancer drugs in metastatic prostate cancer.
Prostate
; 77(11): 1199-1204, 2017 Aug.
Article
in English
| MEDLINE | ID: mdl-28649702
5.
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.
J Nucl Med
; 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38637137
6.
Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617.
Eur Urol Open Sci
; 57: 30-36, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-38020530
7.
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
J Nucl Med
; 64(1): 69-74, 2023 01.
Article
in English
| MEDLINE | ID: mdl-35738906
8.
Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
J Nucl Med
; 64(2): 221-226, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36008120
9.
The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy.
J Nucl Med
; 64(9): 1412-1416, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37348918
10.
177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy.
J Nucl Med
; 64(3): 410-415, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36215568
11.
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Ther Adv Med Oncol
; 15: 17588359231156392, 2023.
Article
in English
| MEDLINE | ID: mdl-36872949
12.
Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series.
Asia Pac J Clin Oncol
; 18(3): 209-216, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-33852771
13.
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial.
J Nucl Med
; 63(4): 560-566, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34326127
14.
Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center.
Asia Pac J Clin Oncol
; 18(2): e23-e31, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34152083
15.
Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue.
Prostate Cancer
; 2022: 6499344, 2022.
Article
in English
| MEDLINE | ID: mdl-35754788
16.
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol).
Ther Adv Med Oncol
; 14: 17588359221092486, 2022.
Article
in English
| MEDLINE | ID: mdl-35465297
17.
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
Eur J Cancer
; 170: 285-295, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35643841
18.
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.
Nat Commun
; 13(1): 6467, 2022 10 29.
Article
in English
| MEDLINE | ID: mdl-36309516
19.
Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).
Eur Urol Oncol
; 4(6): 963-970, 2021 12.
Article
in English
| MEDLINE | ID: mdl-32758400
20.
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.
Cancers (Basel)
; 13(19)2021 Oct 01.
Article
in English
| MEDLINE | ID: mdl-34638448